Faster-acting insulin aspart vs insulin aspart as part of basal–bolus therapy improves postprandial glycaemic control in uncontrolled Type 2 diabetes in the double-blinded onset 2 trial

Saravanan, P.; Bowering, K.; Case, C.; Harvey, J.; Reeves, M.; Sampson, M.; Strzinek, R.; Bretler, D. M.; Bang, R. B.; Bode, B. W.

Author

Saravanan, P.
Bowering, K.
Case, C.
Harvey, J.
Reeves, M.
Sampson, M.
Strzinek, R.
Bretler, D. M.
Bang, R. B.
Bode, B. W.

Affiliation

University of Warwick; George Eliot Hospital, Nuneaton; University of Alberta, Canada; Jefferson City Medical Group, Missouri, USA; Bangor University, UK; Diabetes Clinical Trials, Chattanooga, Tennessee, USA; Norfolk and Norwich University Hospitals NHS Foundation Trust; Protenium Clinical Research, Hurst, Texas, USA; Novo Nordisk A/S, Søborg, Denmark; Atlanta Diabetes Associates, Georgia, USA

Publication date

2017-03-08

Subject

Diabetes

Metadata

Show full item record

Abstract

Poster abstract A46 (P110) in the section Science in clinical practice 1 from the Diabetes UK Professional Conference 2017, Manchester Central, Manchester, 8–10 March 2017.

Citation

Saravanan P, Bowering K, Case C, Harvey J, Reeves M, Sampson M, Strzinek R, Bretler DM, Bang RB, Bode BW. Faster-acting insulin aspart vs insulin aspart as part of basal–bolus therapy improves postprandial glycaemic control in uncontrolled Type 2 diabetes in the double-blinded onset 2 trial. Diabetic Medicine. 2017 Mar;34(S1):21. doi: 10.1111/dme.8_13303.

Type

Conference Output